I think that will be the longest slog. Once we are capitalized again our potential can shine though.
IPIX has a severe financing and credibility problem. We were a reasonably well-capitalized phase 3 ready company at the end of 2014 following a blow-out 200 patient ABSSSI phase 2b.
The company has since regressed with smaller trial successes in earlier phases. Our last was a phase 1 with six people treated. We have now moved on to take pride in our cost-free COVID pre-clinical in vitro work.
A major phase 2b trial failure, terrible handling of information disclosure in that failed trial, major milestone misses, an anemic partnership deal ($420K in revenues so far), and ever deteriorating financing deals have led the stock price on a downward slide of destruction. All good will toward this company has been used up.
We are now listed on the OTC with a stock price of $0.16 and a market cap of ~50M. Basically no institutional money can buy us. Most reatail investors who want in are already in (probably at a substantial loss like most on this board). To top it all off, we had a 22% expansion of the share count last quarter and no ownwership filings so there is substantial pressure on the stock until the source of those shares clears out.
$0.16 to $1.00 will be the fight of this company's life. $1 to $5 will be much easier.
Cheers to that grant money coming in. We're gonna need it.
Go IPIX!
Market Data 
Markets 
AI
